DURHAM, N.C., April 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the Company’s initiation of a Phase 2/3 study of dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI). Yahoo!奇摩股市提供您當日行情、大盤走勢、類股走勢、期貨及選擇權分類報價、港滬深股、美股、財經新聞等資訊。 Nio reports narrower-than-expected loss and revenue that beat forecasts, but stock pulls back Nio Inc. reported Thursday a narrower-than-expected loss and revenue that fell less than forecast, but Disclaimer: The TipRanks Smart Score performance is based on backtested results.Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost
未名博客 - 未名空间 - mitbbs.com 美国批准首款生物仿制药物 2015年03月07日 00:28 新浪财经 新浪财经讯 北京时间3月7日凌晨消息，美国食品药品管理局(fda)周五批准了首款生物
DURHAM, N.C., April 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the Company’s initiation of a Phase 2/3 study of dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury (ALI). Yahoo!奇摩股市提供您當日行情、大盤走勢、類股走勢、期貨及選擇權分類報價、港滬深股、美股、財經新聞等資訊。 Nio reports narrower-than-expected loss and revenue that beat forecasts, but stock pulls back Nio Inc. reported Thursday a narrower-than-expected loss and revenue that fell less than forecast, but Disclaimer: The TipRanks Smart Score performance is based on backtested results.Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost Find the latest Chimerix, Inc. (CMRX) stock quote, history, news and other vital information to help you with your stock trading and investing.
20150921-国信证券-冰与火之歌：技术的游戏-纳斯达克生物技术指 … 20150921-国信证券-冰与火之歌：技术的游戏-纳斯达克生物技术指数强势之谜.pdf,证券研究报告——医药行业海外市场专题报告 冰与火之歌：技术的游戏 ——纳斯达克生物技术指数强势之谜 证券分析师：江维娜 证券投资咨询执业证书编码：S0座机电话号码0001 证券分析师：邓周宇 证券投资咨询执业 《冰与火之歌-技术的游戏-纳斯达克生物技术指数强势之谜》.pdf文 …
Find the latest Chimerix, Inc. (CMRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. News, email and search are just the beginning. Discover more every day. Find your yodel. Chimerix to Present at Jefferies Virtual Healthcare Conference. Chimerix (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 9